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Alzheimer’s disease (AD) is a devastating condition thought
to affect more than 37 million people worldwide, a figure that
is predicted to increase dramatically with an ageing popu-
lation. After the description of AD by Alois Alzheimer in the
early 1900s [1], the last century saw only incremental advances
with respect to our treatment of this neurodegenerative disease.
Cholinesterase inhibitors and memantine, the two approved
therapies for use in patients with AD, provide at best modest
symptomatic benefit and do not appear to significantly alter
the disease course. Recent years have seen great strides in
our knowledge regarding the pathogenic cascades that
trigger the disease, and these advances have been a catalyst
for the development of new therapeutics that are hoped to be
disease modifying.
We have much still to learn about the aetiology and neuro-
pathological processes underlying this growing epidemic,
and Alzheimer’s Research & Therapy will uniquely focus on
the translational aspect of research into Alzheimer’s and other
dementias. The journal will provide a platform to commu-
nicate on methods of developing and measuring interventions
in human studies.
Alzheimer’s Research & Therapy will consider a broad
spectrum of research into the dementias, which is reflected
by our exceptional Editorial Board [2]. We aim to publish
research that relates causal and risk factors with neuro-
degenerative conditions causing dementia, and describes the
potential therapeutic applications of basic research, animal
models, and other model systems, and novel therapeutics.
This will include studies into genetics, molecular neuro-
biology, neuropathology, imaging, and biomarkers, with a
focus on potential applications for intervention. Lessons
learned from animal models, particularly how well they trans-
late into human research, is an important theme. Another
major focus will be on clinical trial design, outcome measure-
ment, and preventative strategies.
In addition to high quality research, we will commission
thought provoking review articles, which provide an account
of recent developments in a given area of research, raise
questions about areas of future development and analyse
existing hypotheses. We will publish shorter opinion pieces of
contemporary interest on any subject within the journal’s
scope. Reader’s suggestions will be welcomed.
All research articles published in Alzheimer’s Research &
Therapy will be open access [3]. This means that all research
articles are freely available online to all readers worldwide.
This ensures high visibility for an author’s work. In addition,
authors will retain their own copyright, making it possible for
them to grant the right to reproduce any part of their pub-
lished research to anyone, provided it is correctly attributed.
Publishing in Alzheimer’s Research & Therapy also means
that an author’s work is deposited automatically in public
archives such as PubMed Central [4]. This is an easy way for
authors to comply with the increasing number of funder’s
public access policy, such as those announced over the past
year by the NIH [5] and the Wellcome Trust [6] for example.
All submitted articles will initially be screened by a member of
the journal’s international Editorial Board [2]. Manuscripts will
be peer reviewed by recognised experts in the dementia field.
Reviewers and editors are asked to declare any potential
conflicts of interest they may have in reviewing a manuscript.
Reviews will be rapid, and once an article is accepted for
publication it will be published online immediately in a
provisional format. Once an article is accepted for
publication, the publisher levies an Article Processing Charge
[7] that covers the costs incurred in the handling of and
adding value to the article. Online publication means that
there are no space restrictions. This charge is a flat fee
independent of article length, and any number of colour
figures and additional data sets can be included in an article
at no extra cost.
Alzheimer’s Research & Therapy will be the major forum for
translational research into Alzheimer’s disease. We are
delighted to introduce this much-needed journal to the
Alzheimer’s research community, and welcome your
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responses and submissions. The Editors are committed to
making this journal a success, and we look forward to
receiving your contributions in the future.
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